Back to list

TRIUMPH

University of North Carolina at Chapel Hill


Description

UNC is conducting a research study that is looking to compare oral Truvada as PrEP with a long-acting injectable medication Cabotegravir in HIV-uninfected men and transgender women who have sex with men. This will require taking oral medication daily and receiving periodic injections. The study requires several visits.


Keywords:

Men's Health, Women's Health


Category:

Drug or Biologic

Qualifications

 


Age
18 - 99 years


Gender
Any


Study Population

Adults - MSM/TGW - HIV-uninfected


Investigator

Christopher Hurt
Clinical Associate Professor
Medicine-Infectious Diseases

For questions, contact:

Alexandra Roos
prevention_study@med.unc.edu
(877) 643-9040
Visit Website

Recruitment Period End

January 25, 2021

Location

Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 99 years

Participant qualification(s) Men and transgender women who have sex with men, HIV-uninfected

Not eligible if: Recent IV drug use, History of seizures

Number of Visits

    » 51 In person visit(s)

    1 Screening, 50 Clinic

    » 0 Remote visit(s)

Participation Period

4.5 years

Compensation

$50 per visit

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.